• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Zogenix Inc.

    3/7/22 11:32:51 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZGNX alert in real time by email
    S-8 POS 1 d302895ds8pos.htm S-8 POS S-8 POS

    Registration No. 333-170875

    Registration No. 333-181543

    Registration No. 333-197998

    Registration No. 333-224797

    Registration No. 333-233062

    Registration No. 333-238804

    Registration No. 333-258532

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    Form S-8 Registration No. 333-170875

    Form S-8 Registration No. 333-181543

    Form S-8 Registration No. 333-197998

    Form S-8 Registration No. 333-224797

    Form S-8 Registration No. 333-233062

    Form S-8 Registration No. 333-238804

    Form S-8 Registration No. 333-258532

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ZOGENIX, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   20-5300780

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    5959 Horton Street, Suite 500

    Emeryville, California

      94608
    (Address of Principal Executive Offices)   (Zip Code)

    Zogenix, Inc. 2006 Equity Incentive Plan

    Zogenix, Inc. 2010 Equity Incentive Award Plan

    Zogenix, Inc. Employee Stock Purchase Plan

    Zogenix, Inc. Employment Inducement Equity Incentive Award Plan

    Zogenix, Inc. 2021 Employment Inducement Equity Incentive Award Plan

    (Full title of the plans)

    Stephen J. Farr, Ph.D.

    President and Chief Executive Officer

    Zogenix, Inc.

    5959 Horton Street, Suite 500

    Emeryville, California

    (Name and address of agent for service)

    (617) 401-4060

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    J. D. Weinberg   Stephen J. Farr, Ph.D.
    Covington & Burling LLP   President,
    The New York Times Building   Chief Executive Officer
    620 Eighth Avenue   Zogenix, Inc.
    New York, New York 10018   5959 Horton Street, Suite 500
    (212) 841-1037   Emeryville, California
        (510) 550-8300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
    Emerging growth company   ☐     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 relates to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”), filed with the Securities and Exchange Commission (the “SEC”) by Zogenix, Inc., a Delaware corporation (the “Registrant”):

     

    •  Registration Statement No. 333-170875, filed with the SEC on November 30, 2010, pertaining to the registration of 4,233,689* shares of the common stock of the Registrant, $0.001 par value per share (the “Common Stock”), reserved for issuance under the Zogenix, Inc. 2010 Equity Incentive Award Plan, as amended from time to time (the “2010 Plan”), 1,482,780* shares of Common Stock subject to outstanding awards under the Zogenix, Inc. 2006 Equity Incentive Plan, as amended from time to time (the “2006 Plan”) and 1,000,000* shares of Common Stock reserved for issuance under the Zogenix, Inc. 2010 Employee Stock Purchase Plan, as subsequently amended and restated effective May 29, 2020 (the “ESPP”);

     

    •  Registration Statement No. 333-181543, filed with the SEC on May 18, 2012, pertaining to the registration of 51,866,311* shares of Common Stock reserved for issuance under the 2010 Plan and 3,900,000* shares of Common Stock subject to outstanding awards granted following the adoption of the amended 2010 Plan by the board of directors of the Registrant (the “Board”) on April 27, 2012;

     

    •  Registration Statement No. 333-197998, filed with the SEC on August 8, 2014, pertaining to the registration of 335,500* shares of Common Stock reserved for issuance under the Zogenix, Inc. Employment Inducement Equity Incentive Award Plan (the “Inducement Plan”), and 2,364,500* shares of Common Stock subject to outstanding awards granted following adoption of the Inducement Plan by the Board on December 4, 2013;

     

    •  Registration Statement No. 333-224797, filed with the SEC on May 9, 2018, pertaining to the registration of 300,000 shares of Common Stock reserved for issuance under the Inducement Plan and 250,000 shares of Common Stock reserved for issuance under the ESPP;

     

    •  Registration Statement No. 333-233062, filed with the SEC on August 7, 2019, pertaining to the registration of 4,000,000 shares of Common Stock reserved for issuance under the 2010 Plan;

     

    •  Registration Statement No. 333-238804, filed with the SEC on May 29, 2020, pertaining to the registration of 500,000 shares of Common Stock reserved for issuance under the ESPP; and

     

    •  Registration Statement No. 333-258532, filed with the SEC on August 6, 2021, pertaining to the registration of 1,000,000 shares of Common Stock reserved for issuance under the Zogenix, Inc. 2021 Employment Inducement Equity Incentive Award Plan and 4,500,000 shares of Common Stock reserved for issuance under the 2010 Plan.

     

    *

    Represents the number of shares registered prior to giving effect to the 8:1 reverse stock split effected on July 1, 2015.

    The Registrant is filing this Post-Effective Amendment No. 1 to the Registration Statements to deregister all securities that remain unsold under the above-referenced Registration Statements.

    On March 7, 2022, pursuant to the terms of an Agreement and Plan of Merger, dated as of January 18, 2022 (the “Merger Agreement”), among UCB S.A., a société anonyme formed under the Laws of Belgium (“Parent”), Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (the “Merger Sub”) and the Registrant, Merger Sub merged with and into the Registrant, with the Registrant surviving the merger as an indirect wholly owned subsidiary of Parent (the “Merger”).

    As a result of the Merger, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unissued at the termination of the offerings, the Registrant hereby removes from registration all securities registered but unsold under such Registration Statements, if any, as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused the Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California on March 7, 2022.

     

    ZOGENIX, INC.
    By:  

    /s/ Stephen J. Farr

      Stephen J. Farr
      President and Chief Executive Officer

    Note: No other person is required to sign these Post-Effective Amendments to the Registration Statements, in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $ZGNX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ZGNX

    DatePrice TargetRatingAnalyst
    2/28/2022Outperform → Market Perform
    Northland Capital
    1/19/2022Buy → Hold
    Needham
    12/20/2021$37.00 → $32.00Outperform
    SVB Leerink
    9/9/2021$23.00Buy
    UBS
    8/6/2021$48.00 → $44.00Buy
    Needham
    8/6/2021$42.00 → $37.00Outperform
    SVB Leerink
    More analyst ratings

    $ZGNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UCB Completes Acquisition of Zogenix, Inc.

      BRUSSELS, Belgium and ATLANTA, March 7, 2022 /PRNewswire/ -- UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ:ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share. The total transaction is valued at up to approximately US $1.9 billion / €1.7 billion*. Charl van Zyl, Executive Vice President, Neurology & Head of Europe/International Markets, UCB, said: "We are very pleased to reach today's milestone at the earliest opportunity

      3/7/22 12:00:00 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022

      Two podium and one poster presentation share important new findings on FINTEPLA's safety profile and its impact on non-seizure related benefits for LGS patientsLGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approximately 30,000-50,000 patients in the U.S.1 EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Mee

      3/4/22 8:00:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunicom Appoints Jennifer Haldeman as Vice President of Commercial Operations

      Executive with decades of leadership in biopharma and entrepreneurship to aid global commercialization efforts for Company's Immunopheresis® therapy Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive therapies for cancer and other autoimmune diseases, today announced Jennifer "J.D." Haldeman has joined the company as Vice President of Commercial Operations. Haldeman brings many decades of executive leadership experience to Immunicom. She has led commercial teams for both private and public companies in the biopharma, diagnostics, and medical device arenas, where she was responsible for launching more than a dozen innovative products. Jennifer spent the first te

      3/1/22 11:35:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FINTEPLA issued to ZOGENIX INC

      Submission status for ZOGENIX INC's drug FINTEPLA (SUPPL-9) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 05/30/2023. Application Category: NDA, Application Number: 212102, Application Classification: REMS

      5/31/23 12:11:20 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FINTEPLA issued to ZOGENIX INC

      Submission status for ZOGENIX INC's drug FINTEPLA (SUPPL-6) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 01/03/2023. Application Category: NDA, Application Number: 212102, Application Classification: Labeling

      1/4/23 12:43:03 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FINTEPLA issued to ZOGENIX INC

      Submission status for ZOGENIX INC's drug FINTEPLA (SUPPL-5) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 06/15/2022. Application Category: NDA, Application Number: 212102, Application Classification: Labeling

      6/16/22 4:37:19 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Smith Michael P closing all direct ownership in the company (withholding obligation)

      4 - ZOGENIX, INC. (0001375151) (Issuer)

      3/9/22 7:19:21 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Breitmeyer James B closing all direct ownership in the company (for tax liability)

      4 - ZOGENIX, INC. (0001375151) (Issuer)

      3/9/22 7:16:42 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Stutts Mary E. to satisfy withholding obligation

      4 - ZOGENIX, INC. (0001375151) (Issuer)

      3/9/22 7:15:11 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zogenix downgraded by Northland Capital

      Northland Capital downgraded Zogenix from Outperform to Market Perform

      2/28/22 1:52:35 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zogenix downgraded by Needham

      Needham downgraded Zogenix from Buy to Hold

      1/19/22 2:38:51 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Zogenix with a new price target

      SVB Leerink reiterated coverage of Zogenix with a rating of Outperform and set a new price target of $32.00 from $37.00 previously

      12/20/21 4:55:58 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    SEC Filings

    See more
    • SEC Form 15-12B filed by Zogenix Inc.

      15-12B - ZOGENIX, INC. (0001375151) (Filer)

      3/17/22 8:00:59 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Zogenix Inc.

      EFFECT - ZOGENIX, INC. (0001375151) (Filer)

      3/8/22 12:15:16 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Zogenix Inc.

      EFFECT - ZOGENIX, INC. (0001375151) (Filer)

      3/8/22 12:15:08 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immunicom Appoints Jennifer Haldeman as Vice President of Commercial Operations

      Executive with decades of leadership in biopharma and entrepreneurship to aid global commercialization efforts for Company's Immunopheresis® therapy Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive therapies for cancer and other autoimmune diseases, today announced Jennifer "J.D." Haldeman has joined the company as Vice President of Commercial Operations. Haldeman brings many decades of executive leadership experience to Immunicom. She has led commercial teams for both private and public companies in the biopharma, diagnostics, and medical device arenas, where she was responsible for launching more than a dozen innovative products. Jennifer spent the first te

      3/1/22 11:35:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

      SC 13G/A - ZOGENIX, INC. (0001375151) (Subject)

      2/14/22 9:05:54 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

      SC 13G/A - ZOGENIX, INC. (0001375151) (Subject)

      2/11/22 11:43:17 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

      SC 13G/A - ZOGENIX, INC. (0001375151) (Subject)

      2/10/22 8:47:19 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZGNX
    Financials

    Live finance-specific insights

    See more
    • Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

      Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced U.S. Food and Drug Administration acceptance with Priority Review of Supplemental New Drug Application for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Submitted Type II Variation Application to the European Medicines Agency to expand the use of FINTEPLA for LGSSubmitted New Drug Application to Japan's Ministry of Health, Labour & Welfare for the marketing approval of FINTEPLA in Dravet syndromePreviously announced agreement to be acquired by UCB; transaction expected to close in the first half of

      2/28/22 8:00:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UCB to acquire Zogenix

      BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ:ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases. Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for a purchase price per share of US$ 26.00 in cash at closing, plus a contingent value right (CVR) for a potential cash payment of US$ 2.00 upon EU approval by December 31, 2023, of FINTEPLA® as an orphan medicine fo

      1/19/22 1:00:00 AM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zogenix Provides Corporate Update and Reports Third Quarter 2021 Financial Results

      FINTEPLA® net product sales of $21.4 million and total revenue of $22.6 million in the third quarter, representing quarter-over-quarter increases of 22% and 20%, respectivelySubmitted supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Continuing to advance late-stage development programs for FINTEPLA and MT1621 EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced financial results for the three and nine months ended September 30, 2021, and provided a corporate update. The Company will host a conferen

      11/4/21 4:05:00 PM ET
      $ZGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care